

# GREECE

## Recent and planned developments in pharmaceutical policies 2023

### CHANGES IN PRICING

2023

#### Annual revision of prices for medicinal products:

- Ministerial Decision D3(a)72397/16.12.2022 and issued with corrections on 05.01.2023
- According to Pricing rules in place (Ministerial Decision D3(a)82331/22.11.2019 & D3(α) οικ.79525 Official Gazette 5511/B/15-12-2020) increases of prices are not allowed. However, an exemption is referred for exceptional circumstances.

2023/02

#### Call for application for prices adjustment:

- On 17<sup>th</sup> February 2023 there is an announcement, based on a ministerial decision, mentioning that with a view to protecting public health, meet the therapeutic needs of patients and the financial sustainability, the MAHs are kindly requested to submit applications for prices adjustments for medicinal products that:
  - have a wide circulation with significant sales,
  - are unique and
  - there is a risk of withdrawal from the Greek market due to their low retail price


### CHANGES IN REIMBURSEMENT

2023/02

#### New Positive Reimbursement List:

- Ministerial Decision D3(a)7719/13.02.2023 for Positive Reimbursement List which includes
  - revision of the reference prices based on annual repricing and
  - inclusion of new products

#### Products introduced in the Positive List



2023/02

#### Renewal of the Committee for Assessment and Reimbursement for Medicinal Products:

- Ministerial Decision D3(a)7719/13.02.2023 refers to the establishment of the HTA and Reimbursement Committee which belongs to the Ministry of Health for 3 years

### OTHER CHANGES

2023/01

#### Establishment of a procedure for reimbursement request under exceptional circumstances for medicinal products not included in the Positive List :

- Ministerial Decree 4547/25.01.2023 which includes a)unmet medical need b)certainty of data c)annual report to the Minister of Health and d)the development of a specific electronic platform

2023/02

#### First Report from Horizon Scanning Activity submitted to the Ministry of Health:

- Recent legislation introduced the obligation to the MAH to declare products for which they intend to submit an application to the HTA and Negotiation Committee the next year (Law 4931/2022 article 71 and Ministerial Decree 52615/05.10.2022

2023/02

#### Re-evaluation of products containing Vitamin D, Mg and Iron

- After re-evaluation of p.os administered products included in the Positive Reimbursement List, restrictions to the approved indications have been applied. In general, only therapy with specific conditions is now reimbursed, while prevention is not covered.

### SPECIAL TOPIC:

#### Developing and implementing pharmaceutical policies in view of the current challenges (soaring inflation, medicine price increases, increasing no. of medicine shortages)

- Medicines shortages**
  - The MAHs must submit to the National Organisation for Medicines (EOF) on a regular basis where they supply their medicines (hospitals, EOPYY, wholesalers)
  - The NDO (EOF) is responsible to temporarily ban exports in case of shortages
  - IFET which is a legal entity which is supervised by EOF and acts as a state warehouse can import medicines to cover national needs
- Price increases**
  - According to the national legislation price increases are not allowed.
  - Under exceptional circumstances and with a request by the Ministry of Health for public health reasons the MAHs could submit for price increases when some predefined criteria are met
- Other measures**
  - A special budget has been introduced for vaccines.
  - Separate budgets for blood derived products (immunoglobulins and albumins) through negotiation procedure have been established.